TECHNOLOGY-BASED
pharmaceutical company Verseon
has announced that it has
developed a new class of oral,
highly selective, direct thrombin
inhibitors which have demonstrated
reduced risk of major bleeding in
comparison with current novel oral
anticoagulants (NOACs).
The announcement was
presented at the Biotech Showcase
Conference in San Francisco this
week.
The early pre-clinical studies have
indicated that the new compounds
have equivalent or better
therapeutic potential, the company
said, adding that they are still a few
years from marketing approvals.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 16
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.